When treating bladder cancer with CRT in the bladder preservation paradigm, do you cone down to partial bladder or the whole bladder?   

I've heard justification for treating the whole bladder to 60-64 Gy based on the UK MRC study (James et al. NEJM 2012 and Huddart et al. IJROBP 2013) and was wondering how often this is done? The UK MRC study used concurrent 5-FU/MMC rather than cisplatin - is there any reason to think that concurrent cis would lead to more toxicity than 5-FU/MMC?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution